Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020

Eurosurveillance - Tập 25 Số 11 - 2020
Anu Haveri1, Teemu Smura2, Suvi Kuivanen2, Pamela Österlund1, Jussi Hepojoki3,2, Niina Ikonen1, Marjaana Pitkäpaasi1, Soile Blomqvist1, Esa Rönkkö1, Anu Kantele4, Tomas Strandin2, Hannimari Kallio‐Kokko5, Laura Mannonen5, Maija Lappalainen5, Markku Broas6, Miao Jiang1,7, Lotta Siira1, T Hovi1, Taneli Puumalainen1, Jussi Sane1, Merit Melin1, Olli Vapalahti5, Carita Savolainen‐Kopra1
1Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
2University of Helsinki, Medicum, Department of Virology, Helsinki, Finland
3Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland
4Inflammation Center, Infectious Diseases, Helsinki University Hospital (HUSLAB) and University of Helsinki, Helsinki, Finland
5Department of Virology and Immunology, Helsinki University Hospital (HUSLAB) and University of Helsinki, Helsinki, Finland
6Infection-Hospital Hygiene Unit, Lapland Central Hospital, Rovaniemi, Finland
7Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland

Tóm tắt

The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3–23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.

Từ khóa


Tài liệu tham khảo

World Health Organization (WHO). Novel Coronavirus (2019-nCoV) Situation report - 1. Geneva: WHO, 21 Jan 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf

Corman, 2020, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR., Euro Surveill, 25, 10.2807/1560-7917.ES.2020.25.3.2000045

Wu, 2020, A new coronavirus associated with human respiratory disease in China., Nature, 579, 265, 10.1038/s41586-020-2008-3

Korzyukov, 2016, Generation of anti-boa immunoglobulin antibodies for serodiagnostic applications, and their use to detect anti-reptarenavirus antibodies in boa constrictor., PLoS One, 11, 10.1371/journal.pone.0158417

Mäkelä, 1998, Viruses and bacteria in the etiology of the common cold., J Clin Microbiol, 36, 539, 10.1128/JCM.36.2.539-542.1998

Ziegler, 2005, Severe acute respiratory syndrome coronavirus fails to activate cytokine-mediated innate immune responses in cultured human monocyte-derived dendritic cells., J Virol, 79, 13800, 10.1128/JVI.79.21.13800-13805.2005

Backer, 2020, Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020., Euro Surveill, 25, 10.2807/1560-7917.ES.2020.25.5.2000062

European Centre for Disease Prevention and Control (ECDC). Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – sixth update. Stockholm: ECDC, 12 Mar 2020. Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-novel-coronavirus-disease-2019-covid-19-pandemic-increased

Hadfield, 2018, Nextstrain: real-time tracking of pathogen evolution., Bioinformatics, 34, 4121, 10.1093/bioinformatics/bty407

World Health Organization (WHO). Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. ISBN 978-92-4-000097-1. Geneva: WHO

17 Jan 2020. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwiOw-i44ZLoAhWWFcAKHZmJCIoQFjAAegQIBBAB&url=https%3A%2F%2Fapps.who.int%2Firis%2Frest%2Fbitstreams%2F1266309%2Fretrieve&usg=AOvVaw1YNVgNwua9Dpj5c-PSD5c8

Zhang, 2020, Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes., Emerg Microbes Infect, 9, 386, 10.1080/22221751.2020.1729071

Bai, 2020, [Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province], Zhonghua Yu Fang Yi Xue Za Zhi, 54

Chen, 2004, Serology of severe acute respiratory syndrome: implications for surveillance and outcome., J Infect Dis, 189, 1158, 10.1086/380397

Gorse, 2020, Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses., J Med Virol, 92, 512, 10.1002/jmv.25715

Woo, 2004, False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide., J Clin Microbiol, 42, 5885, 10.1128/JCM.42.12.5885-5888.2004

Peiris, 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study., Lancet, 361, 1767, 10.1016/S0140-6736(03)13412-5

Chen, Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases. Available online 27 February 2020.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease. Pre-print. 2019medRxiv 2020.03.02.20030189.

Al Kahlout, 2019, Comparative serological study for the prevalence of anti-MERS coronavirus antibodies in high- and low-risk groups in Qatar., J Immunol Res, 2019, 10.1155/2019/1386740

Leung, 2006, Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups., Epidemiol Infect, 134, 211, 10.1017/S0950268805004826

Che, 2005, Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43., J Infect Dis, 191, 2033, 10.1086/430355

Dijkman, 2008, Human coronavirus NL63 and 229E seroconversion in children., J Clin Microbiol, 46, 2368, 10.1128/JCM.00533-08

Wu, 2004, The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells., Cell Res, 14, 400, 10.1038/sj.cr.7290240

Thông tin
Thông tin xuất bản

Eurosurveillance

Tập 25 Số 11

Thông tin tác giả